OncoMatch/Clinical Trials/NCT06441747
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Is NCT06441747 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Durvalumab and Olaparib for cholangiocarcinoma.
Treatment: Durvalumab · Olaparib — The aim of this study is to investigate whether the combination of durvalumab and olaparib in the maintenance setting after initial chemotherapy and durvalumab will benefit patients with locally advanced or metastatic cholangiocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Prior therapy
Must have received: gemcitabine and cisplatin and durvalumab (gemcitabine, cisplatin, durvalumab) — first-line
Must not have had radiologic progression after 6-8 cycles of gemcitabine and cisplatin and durvalumab
Cannot have received: PARP inhibitor
Previous use of a PARP inhibitor
Lab requirements
Blood counts
Haemoglobin ≥ 90g/L (without a transfusion in the past two weeks); Platelets ≥100 x 10^9/L (without a transfusion in the past two weeks); Neutrophils ≥ 1.0 x 10^9/L (without the use of G-CSF in the 4 weeks prior to first dose)
Kidney function
Serum Creatinine ≤1.5 x ULN or eGFR ≥ 30mL/min/1.73m2 as calculated by Cockcroft Gault Equation
Liver function
ALT/AST <3x ULN irrespective of presence of liver metastases; Serum bilirubin ≤ 1.5x ULN except in cases of known Gilbert's Syndrome where total bilirubin must be <4x ULN; Albumin ≥ 25 g/L
Cardiac function
Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) <470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart)
Adequate haematological and end-organ function as defined by the following parameters: Haemoglobin ≥ 90g/L (without a transfusion in the past two weeks); Platelets ≥100 x 10^9/L (without a transfusion in the past two weeks); Neutrophils ≥ 1.0 x 10^9/L (without the use of G-CSF in the 4 weeks prior to first dose); ALT/AST <3x ULN irrespective of presence of liver metastases; Serum bilirubin ≤ 1.5x ULN except in cases of known Gilbert's Syndrome where total bilirubin must be <4x ULN; Albumin ≥ 25 g/L; Serum Creatinine ≤1.5 x ULN or eGFR ≥ 30mL/min/1.73m2 as calculated by Cockcroft Gault Equation; Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) <470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify